Overview

Nintedanib Plus Docetaxel in Japanese Patients With Adenocarcinoma Subtype Non-small Cell Lung Cancer After Failure of First Line Chemotherapy

Status:
Completed

Trial end date:
2017-10-27

Target enrollment:

Participant gender:

Summary

To determine the appropriateness of the dose of nintedanib 200 mg b.i.d. plus docetaxel 75 mg/m2 as starting dose by evaluating the safety in Japanese patients with body surface area (BSA) <1.5 m2 and locally advanced or metastatic adenocarcinoma subtype non-small cell lung cancer (NSCLC) after failure of first line platinum- based chemotherapy

Phase:

Phase 1

Details

Lead Sponsor:

Boehringer Ingelheim

Treatments:

Docetaxel
Nintedanib